Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | INBRX-105 |
Trade Name | |
Synonyms | INBRX105|INBRX 105|ES 101|ES-101|ES101 |
Drug Descriptions |
INBRX-105 (ES 101) is a bispecific antibody that binds to TNFRSF9 (CD137) and PD-L1 (CD274), potentially resulting in enhanced anti-tumor immunity and tumor cell lysis (NCI Drug Dictionary). |
DrugClasses | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 TNFRSF9 Antibody 32 |
CAS Registry Number | NA |
NCIT ID | C159978 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
INBRX-105 | INBRX-105 | 0 | 1 |
INBRX-105 + Pembrolizumab | INBRX-105 Pembrolizumab | 0 | 1 |